Erazo Daniells, Luna Jaime, Preux Pierre-Marie, Boumediene Farid, Couratier Philippe
Institute of Epidemiology and Tropical Neurology, INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, GEIST, Limoges, France.
Department of Neurology, CHU Limoges, Centre de Référence SLA et autres maladies du neurone moteur, Limoges, France, and.
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Feb;23(1-2):4-15. doi: 10.1080/21678421.2021.1909066. Epub 2021 Apr 19.
: Heterogeneity of amyotrophic lateral sclerosis (ALS) has been suggested in terms of epidemiology, phenotypes and genetics between geographic areas and populations. However, there is limited information in Latin America. We conducted a systematic review that aimed to describe the epidemiology, frequency of genetic mutations, clinical characteristics and survival of ALS patients in this region. : We reviewed Medline, Scopus, Scielo and LILACS databases up to April 2020. The search terms "Amyotrophic Lateral Sclerosis" or "Motor Neuron Disease" were used in combination with the list of Latin American countries from the United Nations. All observational studies were included. A methodological overview was performed using the principles of descriptive epidemiology. : Overall, 1364 publications were identified and 36 studies were selected, covering 13 Latin American countries. According to the original reports, ALS occurrence varied among countries with a standardized incidence ranging from 0.3 per 100,000 person-years follow up (PYFU) in Ecuador to 3.6 per 100,000 PYFU in Uruguay. A low proportion of the C9orf72 repeat expansion was reported in Cuba and Brazil. We identified age at onset between 50 and 60 years. Survival time was higher than 40 months in half of the studies. Data from multiethnic populations reported a higher risk of developing ALS in Caucasians compared to admixed and Black populations. : This review provides a perspective of ALS variability across Latin America and highlights specific differences when comparing to Europe and North America. However, we cannot draw firm conclusions because of different methodological concerns within the studies.
肌萎缩侧索硬化症(ALS)在不同地理区域和人群的流行病学、表型及遗传学方面存在异质性。然而,拉丁美洲关于这方面的信息有限。我们开展了一项系统综述,旨在描述该地区ALS患者的流行病学、基因突变频率、临床特征及生存率。
我们检索了截至2020年4月的Medline、Scopus、Scielo和LILACS数据库。检索词为“肌萎缩侧索硬化症”或“运动神经元病”,并与联合国列出的拉丁美洲国家名单相结合。纳入所有观察性研究。运用描述性流行病学原理进行方法学概述。
总体而言,共识别出1364篇文献,选取了36项研究,涵盖13个拉丁美洲国家。根据原始报告,各国ALS发病率有所不同,标准化发病率从厄瓜多尔每10万人年随访(PYFU)0.3例到乌拉圭每10万人年随访3.6例不等。古巴和巴西报告的C9orf72重复扩增比例较低。我们确定发病年龄在50至60岁之间。一半的研究中生存时间超过40个月。来自多民族人群的数据显示,与混血人群和黑人相比,白种人患ALS的风险更高。
本综述提供了拉丁美洲ALS变异性的视角,并突出了与欧洲和北美相比的特定差异。然而,由于各项研究中存在不同的方法学问题,我们无法得出确凿结论。